Eisai Brings Halaven To India With A Tiered-Pricing Strategy
This article was originally published in PharmAsia News
The Japanese drug firm is making a strong bid to make expensive drugs affordable in emerging markets like India. For those who cannot pay, the drug will be made available free of charge.
You may also be interested in...
Japan's Eisai appears set for a significant step up in product introductions in India. Improving access to these medicines for patients in the largely self-pay market is at the fulcrum of its strategy, Dr Sanjit Singh Lamba, managing director of Eisai Pharmaceuticals India Pvt Ltd, tells Scrip. Newer options like a second brand approach may also be evaluated for certain new products to expand access and availability across the country.
MUMBAI - Industry analysts in India often credit GlaxoSmithKline Pharmaceuticals Ltd. for the tailor-made localized approach it takes to market products and price them in a way to suit patients who pay for medical costs largely out-of-pocket
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.